Biopharma: Clinical Trial Pipeline Tracker

研报英文原文证据摘录

Biopharma: Clinical Trial Pipeline Tracker

UpdateM

Upsized/Downsized

Exhibit 9: Trials with increased estimated patient recruitment

Primary Previous Est.

Company Drug Stage Event/Study title Status Est. Size Identifier

Completion Size

A Study to Evaluate the Safety and Tolerability of Efgartigimod

Efgartigimod PH20 SC - prefilled Active, not

Argenx Phase2 PH20 SC Given by Prefilled Syringe in Kidney Transplant Nov-27 33 30 NCT06503731

syringe recruiting

Recipients With Antibody-Mediated Rejection (AMR)

Open-Label Extension Study to Assess the Long-Term Safety

Bristol Myers Squibb KarXT Phase3 and Tolerability of KarXT in Subjects With Psychosis Associated Sep-27 Recruiting 1000 800 NCT05980949

With Alzheimer's Disease (ADEPT-3)

BMS-

A Study to Evaluate BMS-986470 in Healthy Volunteers and

Bristol-Myers Squibb 986470|Famotidine|Pantoprazol Phase1|Phase2 Apr-28 Recruiting 224 184 NCT06481306

Participants With Sickle Cell Disease

e

A Study to Compare Iberdomide Maintenance Versus

Lenalidomide Maintenance Therapy Following Autologous Stem Active, not

Bristol-Myers Squibb Iberdomide|Lenalidomide Phase3 Mar-29 1230 1216 NCT05827016

Cell Transplant in Participants With Newly Diagnosed Multiple recruiting

Myeloma

A Study to Evaluate the Long-term Efficacy and Safety of KarXT

Bristol-Myers Squibb KarXT|KarX-EC Phase3 Jun-29 Recruiting 650 600 NCT06937229

+ KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Phase 2b Study of EVO756 in Adults With Moderate to Severe

Evommune EVO756|EVO756|EVO756 Phase2 May-26 Completed 182 160 NCT06873516

Chronic Spontaneous Urticaria (CSU)

A Study to Evaluate the Efficacy and Safety Study of

Active, not

Incyte povorcitinib|ICS-LABA Phase2 Povorcitinib in Participants With Inadequately Controlled Nov-26 247 240 NCT05851443

recruiting